Russia’s pharma and healthcare sector holds significant growth potential, stemming from the country’s large and&ꦛnbsp;aging population. Rus🍰sia is home to largest pharmaceutical market in Central and Eastern Europe and is a key emerg🎉ing market for multinational pharmaceutical majors. The sector of healthcare and social work activities generated 3.1% of the Russian GDP in 2019 and employed 7.9% of the country’s work💃force. In 2019, total healthcare spending amounted to RUB 5.7tn, equivalent to 5.2% of nominal GDP, with the governꦓment taking the lion’s s💫hare of 58%. The country is a net importer of pharmᩚᩚᩚᩚᩚᩚ⁤⁤⁤⁤ᩚ⁤⁤⁤⁤ᩚ⁤⁤⁤⁤ᩚ𒀱ᩚᩚᩚaceutical products. Multinational pharma groups dominate the domestic drug and medical equipment mark🐈et but local producers have gained market share in recent years, taking advantage of supportive governm🌃ent policy and t🎀he depreciation of the rouble. ​

This report provides a complete and detailed analysis of the pharma and healthcare sector for Russia. EMIS Insights presents in-depth business intelligenc🌠e in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the pharma and healthcare sector in Russia
• Access forecasts for growth in the sector
• View key data on healthcare spending and health insurance in Russia
• Crystallise the forces both driving and restraining this sector in Russia
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Russia
• Build a clear picture of trends and issues for sub-sectors (medical institutions, pharmaceuticals manufacturing and distribution channels).

S💃ee below for a complete table of report contents: